Bristol-Myers Squibb gets FDA breakthrough designation for daclatasvir-based regimen - 0 views
-
Alex Parker on 25 Feb 14PBR Staff Writer Published 25 February 2014 Bristol-Myers Squibb (BMS) has received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for its investigational DCV Dual Regimen (daclatasvir and asunaprevir) for use as a combination therapy in the treatment of genotype 1b chronic hepatitis C infection (HCV).